Observations placeholder
Tequin [other names Gatifloxacin, Gatiflo, and Zymar]
Identifier
015724
Type of Spiritual Experience
Background
A description of the experience
Gatifloxacin sold under the brand names Gatiflo, Tequin and Zymar, is an antibiotic. A Canadian study published in the New England Journal of Medicine in March 2006 claims Tequin can have significant side effects including dysglycemia. An editorial by Dr. Jerry Gurwitz in the same issue called for the Food and Drug Administration (FDA) to consider giving Tequin a black box warning. This editorial followed distribution of a letter dated February 15 by Bristol-Myers Squibb to health care providers indicating action taken with the FDA to strengthen warnings for the medication. Subsequently it was reported on May 1, 2006 that Bristol-Myers Squibb would stop manufacture of Tequin, end sales of the drug after existing stockpiles were exhausted, and return all rights to Kyorin. Union Health and Family Welfare Ministry of India on 18 March 2011 banned the manufacture, sale and distribution of Gatifloxacin as it caused certain adverse side effects.
On Apr, 1, 2015: 4,427 people reported to have side effects when taking Tequin. Among them, 66 people (1.49%) have Hallucination.
On Jan, 16, 2017 1,467 people reported to have side effects when taking Gatifloxacin. Among them, 16 people (1.09%) have Hallucination
On Apr, 1, 2015: 1,374 people reported to have side effects when taking Gatifloxacin. Among them, 15 people (1.09%) have Death.
On Apr, 1, 2015: 4,427 people reported to have side effects when taking Tequin. Among them, 80 people (1.81%) have Death.
Time on Tequin when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death77.78%22.22%0.00%0.00%0.00%0.00%0.00%